BiotechTube

Evolocumab + Standard of Care

Phase 3Completed
0 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Hyperlipidemia and Mixed Dyslipidemia

Conditions

Hyperlipidemia and Mixed Dyslipidemia

Trial Timeline

Apr 23, 2013 → May 31, 2018

NCT ID
NCT01854918

About Evolocumab + Standard of Care

Evolocumab + Standard of Care is a phase 3 stage product being developed by Amgen for Hyperlipidemia and Mixed Dyslipidemia. The current trial status is completed. This product is registered under clinical trial identifier NCT01854918. Target conditions include Hyperlipidemia and Mixed Dyslipidemia.

What happened to similar drugs?

8 of 20 similar drugs in Hyperlipidemia and Mixed Dyslipidemia were approved

Approved (8) Terminated (2) Active (11)
✅Diet+pravastatinDaiichi SankyoApproved
✅Bempedoic acid 180 mg tabletDaiichi SankyoApproved
✅Minute Maid Heart Wise orange juice + WelcholDaiichi SankyoApproved
✅Rosuvastatin (Crestor)AstraZenecaApproved
✅simvastatin + EzetimibeMerckApproved
✅Evolocumab + Statins (Cardiovascular Agents)AmgenApproved
✅atorvastatin + atorvastatin + atorvastatinPfizerApproved

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01854918Phase 3Completed

Competing Products

20 competing products in Hyperlipidemia and Mixed Dyslipidemia

See all competitors
ProductCompanyStageHype Score
DRL-17822 or placeboDr. Reddy's LaboratoriesPhase 2
32
VK2809 + PlaceboViking TherapeuticsPhase 2
32
YHP1701 + YHR1703 + YHR1704YuhanPhase 3
40
YH16410 + Rosuvastatin + Telmisartan + YH16410 placebo + Rosuvastatin placebo + Telmisartan placeboYuhanPhase 3
40
Diet+pravastatinDaiichi SankyoApproved
43
Bempedoic acid 180 mg tabletDaiichi SankyoApproved
43
Minute Maid Heart Wise orange juice + WelcholDaiichi SankyoApproved
43
Pravafen + Pravastatin + FenofibrateShionogiPhase 3
40
Evacetrapib + Atorvastatin + Ezetimibe + PlaceboEli LillyPhase 3
32
exenatideEli LillyPre-clinical
26
LY3015014 IV + Placebo IV + LY3015014 SC + Placebo SCEli LillyPhase 1
29
SHR-1209 single-site subcutaneous injection + SHR-1209 multiple-site subcutaneous injectionsJiangsu Hengrui MedicinePhase 1
33
SHR-1209Jiangsu Hengrui MedicinePhase 1
29
SHR-1209 + PlaceboJiangsu Hengrui MedicinePhase 1/2
32
Rosuvastatin + AtorvastatinAstraZenecaPhase 2
35
Rosuvastatin (Crestor)AstraZenecaApproved
39
simvastatin + EzetimibeMerckApproved
43
MK-0524A + Atorvastatin + SimvastatinMerckPhase 3
40
simvastatin 20 mg/ezetimibeMerckPhase 2/3
38
Enlicitide + Rosuvastatin + Placebo for Enlicitide + Placebo for RosuvastatinMerckPhase 3
47